Pure Global
NCT06059261

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

A Prospective, Single-arm, Phase II Study of Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin in Locally Advanced Nasopharyngeal Carcinoma.
Chongqing University Cancer Hospital·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Nasopharyngeal Carcinoma
Drug/Device/Intervention
Envafolimab and recombinant human endostatin combined with chemoradiotherapy
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chongqing University Cancer Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Oct 01, 2023
End date
Oct 01, 2027
Enrollment
30 participants
Primary outcome

Progress-free survival (PFS)

Summary

This is a single-center, prospective, single-arm, phase II clinical study, with the purpose
 to evaluate the therapeutic efficacy and safety of envafolimab combined with
 chemoradiotherapy and recombinant human endostatin in patients with locally advanced
 nasopharyngeal carcinoma.

ICD-10 classifications
Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06059261
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06059261 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chongqing University Cancer Hospital and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.